A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs CLR 1404 I-131 (Primary)
- Indications Brain cancer; Ewing's sarcoma; Glioma; Hodgkin's disease; Lymphoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Cellectar Biosciences
- 20 Dec 2018 Planned initiation date changed from 1 Jul 2018 to 1 Jan 2019.
- 13 Aug 2018 According to a Cellectar Biosciences media release,company has received clearance from the FDA for this trial.
- 09 Jul 2018 According to a Cellectar Biosciences media release, company currently initiating this study.